T1DM Therapeutics in Major Developed Markets Forecast to Year 2021 3 | Page 4

2.10.1 Basal Insulin for MDI Therapy 26
2.10.2 Bolus Insulin for MDI Therapy 33
2.10.3 Bolus Insulin for CSII 37
3 Marketed Products 40
3.1 Overview 40
3.2 Human Insulin Products 42
3.2.1 Humulin Products – Eli Lilly 42
3.2.2 Novolin Products – Novo Nordisk 44
3.2.3 Afrezza (insulin human) – Sanofi and MannKind Corporation 45
3.3 Insulin Analog Products 46
3.3.1 Humalog (insulin lispro) – Eli Lilly and Company 46
3.3.2 Novolog (insulin aspart) Products – Novo Nordisk 48
3.3.3 Apidra (insulin glulisine) - Sanofi 49
3.3.4 Lantus (insulin glargine) - Sanofi 50
3.3.5 Levemir (insulin detemir) – Novo Nordisk 52
3.3.6 Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart) – Novo Nordisk
53
3.3.7 Toujeo (insulin glargine) – Sanofi 55
4 Pipeline 57
4.1 Overview 57
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
58
4.3 Pipeline Distribution by Molecular Target 61
4.3.1 Molecular Target Groups in the Pipeline 64
4.4 Clinical Trial Landscape 69
4.4.1 Clinical Trial Failure Rates 69